There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF-D


VEGF-D Molecule Information

Name:Vascular endothelial growth factor D
Target Synonym:VEGF-D;VEGFD;FIGF;c-Fos-induced growth factor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase ?

VEGF-D Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VED-H5228 Human Human VEGF-D Protein, His Tag

VEGF-D Part of Bioactivity data

Human VEGF-D, His TagHuman VEGF-D, His Tag (Cat. No. VED-H5228) ELISA bioactivity

Immobilized Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) at 5 μg/mL (100 μL/well) can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with a linear range of 0.08-0.6 μg/mL (QC tested).

VEGF-D Molecule Synonym Name


VEGF-D Molecule Background

Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.

VEGF-D References

VEGF-D Related Molecule

VEGF-D Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
OPT-302 OPT-302; VGX-300,OPT302; VGX300,OPT 302; VGX 300 Phase Ⅱ Orphan Europe Age-related macular degeneration (AMD), Diabetic macular edema Details
Taberminogene vadenovec Phase Ⅲ Ark Therapeutics Vascular restenosis Details

This web search service is supported by Google Inc.